Over the past year, I noticed several books written by giants in our field, people everyone knows, people I am honored to know personally. I was interested in what they wrote, and I thought their books would be of general interest to The Cancer Letter community.
Directors of the first three NCI-designated Comprehensive Cancer Centers are learning from the past, starting with the National Cancer Act, and mapping an equitable future for oncology.
When the Cancer History Project launched in January, co-editors Otis Brawley and Paul Goldberg laid out a plan to build a lasting resource for the history of oncology (The Cancer Letter, Jan. 8, 2021). It was “the beginning of a process of storytelling.”
The Office of Inspector General issued a review of FDA’s Accelerated Approval pathway.
Jim Gabriele was named president and chief executive officer of M2GEN.
Memorial Sloan Kettering Cancer Center has established MSKCC India to provide cancer patients in India with access to the institution’s oncologists, research, clinical trials, and education.
Researchers from Queen’s University Belfast, the Northern Ireland Cancer Registry, the International Agency for Research on Cancer and the Union for International Cancer Control have developed CanStaging+, a user-friendly tool aimed at facilitating the recording of comparable cancer staging data worldwide.
The phase III KEYNOTE-716 trial investigating Keytruda, Merck’s anti-PD-1 therapy, met its primary endpoint of recurrence-free survival for the adjuvant treatment of patients with surgically resected high-risk stage II melanoma.
Scientists at St. Jude Children’s Research Hospital are working with colleagues in China to develop better therapy for childhood acute lymphoblastic leukemia.
St. Jude Children’s Research Hospital investigators have demonstrated that comprehensive genomic sequencing of all pediatric cancer patients is feasible and essential to capitalize on the lifesaving potential of precision medicine.
